Use of Ephedra-containing products and risk for hemorrhagic stroke

L. B. Morgenstern, C. M. Viscoli, W. N. Kernan, L. M. Brass, J. P. Broderick, E. Feldmann, J. L. Wilterdink, T. Brott, R. I. Horwitz

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


This case-control study examined the association between Ephedra use and risk for hemorrhagic stroke. For use of Ephedra at any dose during the 3 days before the stroke, the adjusted OR was 1.00 (95% CI 0.32 to 3.11). For daily doses of ≥32 mg/day, the OR was 0.13 (95% CI 0.01 to 1.54), and for >32 mg/day, the OR was 3.59 (95% CI 0.70 to 18.35). Ephedra is not associated with increased risk for hemorrhagic stroke, except possibly at higher doses.

Original languageEnglish (US)
Pages (from-to)132-135
Number of pages4
Issue number1
StatePublished - Jan 14 2003

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Use of Ephedra-containing products and risk for hemorrhagic stroke'. Together they form a unique fingerprint.

Cite this